BACKGROUND/AIM: Recently, several studies have reported that CD103 + T cells are associated with antitumor immunity in gastric cancer (GC). However, the significance of CD103 + T cells in Borrmann type 4 GC remains unclear. The aim of this study is to assess the association of CD103 + T cells with type 4 GC. MATERIALS AND METHODS: Tissue samples obtained from surgically resected specimens of patients with type 4 GC were collected, and immunohistochemical staining was performed to detect the presence of CD103 + T cells. RESULTS: A total of 46 patients were analyzed. In some patients, high CD103 expression was observed, and patients with high CD103 expression tended to have a better prognosis than those with low CD103 expression. In particular, for patients who receive doublet chemotherapy after surgery, high CD103 expression was associated with a good prognosis. CONCLUSION: CD103 + T cells may be a prognostic marker in type 4 GC. Copyright 2022, International Institute of Anticancer Research.
BACKGROUND/AIM: Recently, several studies have reported that CD103 + T cells are associated with antitumor immunity in gastric cancer (GC). However, the significance of CD103 + T cells in Borrmann type 4 GC remains unclear. The aim of this study is to assess the association of CD103 + T cells with type 4 GC. MATERIALS AND METHODS: Tissue samples obtained from surgically resected specimens of patients with type 4 GC were collected, and immunohistochemical staining was performed to detect the presence of CD103 + T cells. RESULTS: A total of 46 patients were analyzed. In some patients, high CD103 expression was observed, and patients with high CD103 expression tended to have a better prognosis than those with low CD103 expression. In particular, for patients who receive doublet chemotherapy after surgery, high CD103 expression was associated with a good prognosis. CONCLUSION: CD103 + T cells may be a prognostic marker in type 4 GC. Copyright 2022, International Institute of Anticancer Research.
Entities:
Keywords:
CD103; Gastric cancer; diffuse type; type 4
Authors: Anusha-Preethi Ganesan; James Clarke; Oliver Wood; Eva M Garrido-Martin; Serena J Chee; Toby Mellows; Daniela Samaniego-Castruita; Divya Singh; Grégory Seumois; Aiman Alzetani; Edwin Woo; Peter S Friedmann; Emma V King; Gareth J Thomas; Tilman Sanchez-Elsner; Pandurangan Vijayanand; Christian H Ottensmeier Journal: Nat Immunol Date: 2017-06-19 Impact factor: 25.606
Authors: H Shiozaki; H Tahara; H Oka; M Miyata; K Kobayashi; S Tamura; K Iihara; Y Doki; S Hirano; M Takeichi Journal: Am J Pathol Date: 1991-07 Impact factor: 4.307
Authors: Laura K Mackay; Azad Rahimpour; Joel Z Ma; Nicholas Collins; Angus T Stock; Ming-Li Hafon; Javier Vega-Ramos; Pilar Lauzurica; Scott N Mueller; Tijana Stefanovic; David C Tscharke; William R Heath; Michael Inouye; Francis R Carbone; Thomas Gebhardt Journal: Nat Immunol Date: 2013-10-27 Impact factor: 25.606